The 9th edition of India Pharma 2026, the flagship event of the Department of Pharmaceuticals under India's Ministry of Chemicals and Fertilizers, has spotlighted India's growing influence in the global…
On March 20, 2026, Novo Nordisk's patent on semaglutide expired in India, triggering one of the most significant transformations in the country's pharmaceutical history. Within weeks, more than 40 Indian…
The Central Drugs Standard Control Organization (CDSCO) is undertaking its most significant regulatory transformation in decades. In a series of reforms announced in early 2026, India's drug regulator has unveiled…
The Central Drugs Standard Control Organization (CDSCO), India's national drug regulatory authority, has undertaken the most significant regulatory modernization in its history during the first half of 2026. From introducing…